Loading company details...
Beta
Latest Form 4 (Sep 4, 2026): David Moatazedi (President and Chief Executive Officer): Sale of 105,108 shares, $950.0K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 4, 2026 | David Moatazedi, President and Chief Executive Officer | Sale | 105,108 | $950.0K |
| Mar 20, 2026 | Rui Avelar | Sale | 3,119 | $14.8K |
| Mar 20, 2026 | David Moatazedi, President & Chief Executive Officer | Sale | 13,669 | $64.9K |
| Mar 19, 2026 | David Moatazedi, President and Chief Executive Officer | Exercise/Conversion | 67,489 | n/a |
| Mar 19, 2026 | Rui Avelar, Chief Medical Officer and Head of Research & Development | Exercise/Conversion | 8,804 | n/a |
| Feb 20, 2026 | Karah Herdman Parschauer | Grant/Award | 45,559 | n/a |
| Feb 20, 2026 | Brady Stewart | Grant/Award | 45,559 | n/a |
| Feb 20, 2026 | Tatjana Mitchell, Chief Financial Officer | Grant/Award | 121,489 | n/a |
| Feb 20, 2026 | Albert G. White III | Grant/Award | 45,559 | n/a |
| Feb 20, 2026 | David Moatazedi, President and Chief Executive Officer | Grant/Award | 313,212 | n/a |